Broadhurst Vanessa

Broadhurst Vanessa, EVP of Global Corporate Affairs, has demonstrated a consistent pattern of selling activity across two companies—Zoetis (ZTS) and Johnson & Johnson (JNJ)—with no recorded purchases in her SEC Form 4 filings. Over 29 reported transactions, her total sell value exceeds $4.64 million, with no offsetting buys. Recent activity reinforces this trend: on February 17, 2026, she sold $1.51 million worth of JNJ shares, following earlier dispositions totaling $916,573 and $352,215 in mid-February. Her ZTS transactions, while smaller, also reflect a sell bias, including a $65,804 sale on February 19, 2026, and a $68,606 transaction in July 2025. The filings show that Broadhurst’s disposals are concentrated in JNJ, where her largest sales—including a $1.44 million transaction in March 2024—account for the bulk of her activity. Many filings include code "F" (tax-related) or "S" (open-market sales), with no recent acquisitions beyond routine awards (code "A") with zero reported value. The absence of buy transactions and the recurring sell-offs suggest a deliberate reduction in equity exposure across both holdings. While the reasons remain undisclosed, the data reflects a clear directional bias toward divestment over the past two years.